0001209191-21-047978.txt : 20210723 0001209191-21-047978.hdr.sgml : 20210723 20210723170018 ACCESSION NUMBER: 0001209191-21-047978 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210721 FILED AS OF DATE: 20210723 DATE AS OF CHANGE: 20210723 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pang Phillip CENTRAL INDEX KEY: 0001787370 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 211111497 MAIL ADDRESS: STREET 1: C/O VIR BIOTECHNOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-21 0 0001706431 Vir Biotechnology, Inc. VIR 0001787370 Pang Phillip C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 1 0 0 Chief Medical Officer Common Stock 2021-07-21 4 M 0 4630 1.575 A 113907 D Common Stock 2021-07-21 4 S 0 4630 37.44 D 109277 D Stock Option (Right to Buy) 1.575 2021-07-21 4 M 0 4630 0.00 D 2028-07-19 Common Stock 4630 43982 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.12 to $37.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Howard Horn, Attorney-in-Fact 2021-07-23